A Granisetron Patch (Sancuso)

Abramowicz, Mark; Zuccotti, Gianna; Pflomm, Jean Marie; Daron, Susan M.; Houst, Blaine M.; Zanone, Corinne E.; Dalton, Vanessa K.; Epstein, Eric J.; Hirsch, Jules; Juurlink, David N.; Kim, Richard B.; Mandell, Gerald L.; Meinertz, Hans; Roden, Dan M.; Simons, F. Estelle R.; Steigbigel, Neal H.; Faucard, Amy; Covey, Cynthia Macapagal; Schwartz, Lauren K.; Cassagnol, Manouchkathe; Brown, Cheryl; Donohue, Liz; Wong, Susie; Carbona, Gene; Romatowski, Cristine; Valentino, Joanne F.; Wissner-Levy, Yosef

doi:10.1097/01.aog.0000347993.73444.2d

Obstetrics &Amp; Gynecology

2009

DOI: 10.1097/01.aog.0000347993.73444.2d

|View full text |Cite

A Granisetron Patch (Sancuso)

Mark Abramowicz¹,

Gianna Zuccotti

Jean Marie Pflomm³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2023

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

Tuca¹

2009

CMAR

View full text Add to dashboard Cite

Until now only intravenous and oral formulations of 5HT 3 receptor antagonists have been available. Recently a new formulation of a 5HT 3 receptor antagonist, transdermal granisetron, has been developed, and approved by the FDA. Three phase I studies to evaluate its pharmacokinetic profile have shown that granisetron administered by a transdermal delivery system is absorbed by passive diffusion and maximal concentration is reached 48 hours after patch application. The patch of 52 cm 2 , which contains 34.3 mg of granisetron, releases 3.3 mg of the drug every day and maintains a stable average plasma concentration of 2.2 ng/mL over 6 days, similar to levels obtained with 2 mg of oral granisetron, administered every day during the same period of time. Two randomized as yet unpublished clinical trials (phase II/III) have been conducted to evaluate the antiemetic efficacy of transdermal granisetron in chemotherapy-induced nausea and vomiting, in patients receiving moderately and highly emetogenic chemotherapy, compared with 2 mg of oral granisetron. More than 800 cancer patients were included in the trials. The rate of complete control of acute emesis was 49% for the phase II trial and 60% for the phase III trial. Neither trial showed a statistically significant difference between transdermal and oral granisetron. The control of delayed emesis was observed in 46% of patients, and there were no statistically significant differences between transdermal and oral granisetron. The most common adverse effects in both trials were constipation (7%) and headache (1%); there were no statistically significant differences between transdermal and oral granisetron. These data show that transdermal granisetron is effective and safe in controlling acute emesis induced by chemotherapy with both moderate and high emetogenic potential. Efficacy and safety of transdermal granisetron are fully comparable with that of oral granisetron. More clinical trials using regimens of 2 or 3 drugs, including dexamethasone and/or aprepitant, are needed to confirm the place of transdermal granisetron in the control of chemotherapy-induced nausea and vomiting.

show abstract

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

Tuca¹

2009

CMAR

View full text Add to dashboard Cite

show abstract

Recent Advancement of Medical Patch for Transdermal Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Transdermal patches are a non-invasive method of drug administration. It is an adhesive patch designed to deliver a specific dose of medication through the skin and into the bloodstream throughout the body. Transdermal drug delivery has several advantages over other routes of administration, for instance, it is less invasive, patient-friendly, and has the ability to bypass first-pass metabolism and the destructive acidic environment of the stomach that occurs upon the oral ingestion of drugs. For decades, transdermal patches have attracted attention and were used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various diseases or conditions. Recently, this method is also being explored as a means of delivering biologics in various applications. Here, we review the existing literatures on the design and usage of medical patches in transdermal drug delivery, with a focus on the recent advances in innovation and technology that led to the emergence of smart, dissolvable/biodegradable, and high-loading/release, as well as 3D-printed patches.

show abstract

Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study

Midani

Parkman

2016

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsSerotonin receptor (eg, antagonists are used to treat nausea and vomiting from a variety of causes. Granisetron transdermal system (GTS) is an appealing delivery system for patients with gastroparesis. To assess if GTS improves nausea and vomiting and other gastroparesis symptoms in patients with gastroparesis. MethodsPatients with gastroparesis and symptoms of nausea and vomiting refractory to conventional treatment were treated with GTS. Symptoms of gastroparesis were assessed using a modified Gastroparesis Cardinal Symptom Index (GCSI). Following 2 weeks of treatment, patients were asked to assess their symptoms and indicate their therapeutic response using the Clinical Patient Grading Assessment Scale (CPGAS) reporting if symptoms of nausea and vomiting improved on a scale: 0 = no change to +7 = completely better. ResultsFifty-one patients received GTS by prescription: average age was 40 ± 17 years, 44 female, 11 diabetics, 23 ± 20% retention at 4 hours on gastric emptying scintigraphy. Thirty-nine of the 51 (76%) patients stated improvement with GTS. There was significant improvement in nausea and vomiting as assessed with CPGAS at 2 weeks (2.28 ± 2.53; P < 0.05). Symptoms of nausea and vomiting significantly improved. Other symptoms including postprandial fullness, loss of appetite, upper abdominal pain, and early satiety improved. Side effects reported included redness at the site of the patch in 7 patients, pruritus in 5, and constipation in 5. ConclusionsGTS was moderately effective in reducing nausea and/or vomiting in 76% of gastroparesis patients. In addition to nausea and vomiting, symptoms of postprandial fullness, loss of appetite, upper abdominal pain, and early satiety also improved.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Granisetron Patch (Sancuso)

Cited by 3 publications

References 3 publications

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

Recent Advancement of Medical Patch for Transdermal Drug Delivery

Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study

Contact Info

Product

Resources

About